●药闻快报▲关注药财社聚焦医药界▲1和誉医药首个自研创新药获批近日,国家药监局(NMPA)官网显示,张江药谷企业和誉医药自主研发的CSF-1R高选择性小分子抑制剂匹米替尼(pimicotinib)获批上市,用于治疗手术切除可能会导致功能受限或出现较严重并发症的症状性成人腱鞘巨细胞瘤(TGCT)患者。据悉,该药物是和誉医药旗下首个获批上市的自研创新药产品,也是中国首个自主研发的腱鞘巨细胞瘤(TGCT...
Source Link●药闻快报▲关注药财社聚焦医药界▲1和誉医药首个自研创新药获批近日,国家药监局(NMPA)官网显示,张江药谷企业和誉医药自主研发的CSF-1R高选择性小分子抑制剂匹米替尼(pimicotinib)获批上市,用于治疗手术切除可能会导致功能受限或出现较严重并发症的症状性成人腱鞘巨细胞瘤(TGCT)患者。据悉,该药物是和誉医药旗下首个获批上市的自研创新药产品,也是中国首个自主研发的腱鞘巨细胞瘤(TGCT...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.